Hangzhou Diagens Biotech shareholders approved 2025 annual report at AGM

• Hangzhou Diagens Biotechnology held its 2025 annual general meeting on June 26, 2026.
• Shareholders adopted the annual report, approved the profit distribution plan, endorsed the annual financial report, accepted the 2026 financial budget.
• Reappointment of Ernst & Young as auditor for 2026 was approved, with the board authorized to set its remuneration.
• A general mandate to issue new shares or sell or transfer treasury shares, capped at 20% of shares in issue, was approved.
• A general mandate to repurchase H shares, capped at 10% of H shares in issue, was approved; amendments to the articles of association were approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Diagens Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260626-12217654), on June 26, 2026, and is solely responsible for the information contained therein.